Collaborative Gamma-Delta T-cell Assets
Oncology
Various (Partner-led)Active via Partnership
Key Facts
About Editas Medicine
Editas Medicine is a clinical-stage leader in CRISPR-based gene editing, founded in 2013 and headquartered in Cambridge, Massachusetts. The company's strategy centers on developing in vivo gene editing medicines, with its most advanced program, EDIT-401 for hyperlipidemia, poised for human proof-of-concept by end of 2026. While facing a competitive landscape and significant clinical and financial risks, Editas possesses foundational IP and a differentiated platform that could yield best-in-class, potentially curative therapies.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |